REGN
Regeneron Pharmaceuticals, Inc.NASDAQHealthcare$761.85-1.98%ClosedMarket Cap: $79.16B
As of 2026-04-06
Valuation
P/E (TTM)
17.57
PEG
8.40
P/B
2.51
P/S
5.52
EV/EBITDA
13.53
DCF Value
$1,969.62
FCF Yield
5.2%
Div Yield
0.5%
Margins & Returns
Gross Margin
85.4%
Operating Margin
24.9%
Net Margin
31.4%
ROE
14.8%
ROA
11.5%
ROIC
8.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.88B | 84.9% | $879.9M | $844.6M | $7.86 | $0.88 |
| FY 2025 | $14.34B | 85.4% | $3.58B | $4.50B | $41.48 | $3.52 |
| Q3 2025 | $3.75B | 86.1% | $1.03B | $1.46B | $13.62 | $0.88 |
| Q2 2025 | $3.68B | 85.6% | $1.08B | $1.39B | $12.81 | $0.88 |
| Q1 2025 | $3.03B | 84.7% | $591.7M | $808.7M | $7.27 | $0.88 |
| Q4 2024 | $3.79B | 85.1% | $990.2M | $917.7M | $8.06 | — |
| FY 2024 | $14.20B | 86.1% | $3.99B | $4.41B | $38.34 | — |
| Q3 2024 | $3.72B | 86.8% | $1.18B | $1.34B | $11.54 | — |
| Q2 2024 | $3.55B | 86.5% | $1.07B | $1.43B | $12.41 | — |
| Q1 2024 | $3.15B | 86.2% | $751.4M | $722.0M | $6.27 | — |
| Q4 2023 | $3.43B | 81.7% | $1.05B | $1.16B | $10.19 | — |
| FY 2023 | $13.12B | 82.9% | $4.35B | $3.95B | $34.77 | — |